Procyrion's Circulatory Pump for Late-Stage Heart Failure Earns Spot in TCT Interventional Innovation "Shark Tank” Competition
Diagnostic and therapeutic modalities presented at Transcatheter Cardiovascular Therapeutics annual scientific symposium.
Houston, TX, October 02, 2015 --(PR.com)-- Aortix™, developed as a low risk, percutaneous solution for late-stage ambulatory heart failure patients, has earned a spot among the revolutionary diagnostic and therapeutic modalities accepted to be presented in the Interventional Innovation “Shark Tank” Competition at the Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium on Tuesday, October 13 in San Francisco, California.
Developed by Procyrion Inc., Aortix is designed to be the first catheter-based circulatory heart pump specifically for NYHA Class III-IVa heart failure patients who are too sick for medication alone, but not sick enough for risky surgical interventions (i.e. LVAD or transplant). The small but powerful micro-pump is deployed downstream of the carotid arteries, which has the potential to eliminate major risks associated with thrombotic strokes, and the device is suitable for ambulatory use.
Duke University cardiologist and Procyrion Scientific Advisory Board member Dr. Manesh Patel will have eight minutes to present the novel booster pump before a unique group of reviewers who will select the best technological concepts of the year. The top three finalists will be selected to answer additional questions from the judges and the winner and first-runner up will be announced Thursday, October 15.
“This is a great opportunity to showcase the potential benefits of Aortix and our exciting preclinical results in front of an audience of prospective users. We believe Aortix has the potential to one-day offer a new ambulatory treatment option for millions of patients with chronic heart failure. TCT is a premier conference for interventional cardiology technologies, and it is an honor to be participating as one of the finalists with so many other worthy candidates,” said Benjamin A. Hertzog, Ph.D., CEO of Procyrion.
TCT, the annual symposium of the Cardiovascular Research Foundation, is the world’s largest educational meeting specializing in interventional cardiovascular medicine. Designed for interventional cardiologists, scientists, cardiac and vascular surgeons and others with a special interest in the field, TCT aims to provide the latest evidence-based data and technological advances to improve patient care. For more about TCT, visit www.tctconference.com.
The Aortix device is not approved for use or sale.
About Procyrion
Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump for ambulatory use. The device is designed to rest and heal the heart by reducing afterload while simultaneously improving blood flow to vital organs. This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, is expected to provide a minimally invasive treatment option for millions of chronic heart failure patients. For more information, visit procyrion.com or call 713.579.9227.
Developed by Procyrion Inc., Aortix is designed to be the first catheter-based circulatory heart pump specifically for NYHA Class III-IVa heart failure patients who are too sick for medication alone, but not sick enough for risky surgical interventions (i.e. LVAD or transplant). The small but powerful micro-pump is deployed downstream of the carotid arteries, which has the potential to eliminate major risks associated with thrombotic strokes, and the device is suitable for ambulatory use.
Duke University cardiologist and Procyrion Scientific Advisory Board member Dr. Manesh Patel will have eight minutes to present the novel booster pump before a unique group of reviewers who will select the best technological concepts of the year. The top three finalists will be selected to answer additional questions from the judges and the winner and first-runner up will be announced Thursday, October 15.
“This is a great opportunity to showcase the potential benefits of Aortix and our exciting preclinical results in front of an audience of prospective users. We believe Aortix has the potential to one-day offer a new ambulatory treatment option for millions of patients with chronic heart failure. TCT is a premier conference for interventional cardiology technologies, and it is an honor to be participating as one of the finalists with so many other worthy candidates,” said Benjamin A. Hertzog, Ph.D., CEO of Procyrion.
TCT, the annual symposium of the Cardiovascular Research Foundation, is the world’s largest educational meeting specializing in interventional cardiovascular medicine. Designed for interventional cardiologists, scientists, cardiac and vascular surgeons and others with a special interest in the field, TCT aims to provide the latest evidence-based data and technological advances to improve patient care. For more about TCT, visit www.tctconference.com.
The Aortix device is not approved for use or sale.
About Procyrion
Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump for ambulatory use. The device is designed to rest and heal the heart by reducing afterload while simultaneously improving blood flow to vital organs. This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, is expected to provide a minimally invasive treatment option for millions of chronic heart failure patients. For more information, visit procyrion.com or call 713.579.9227.
Contact
Procyrion Inc
Anna Halvorson
713.510.0500
www.procyrion.com
Anna Halvorson
713.510.0500
www.procyrion.com
Contact
Categories